Welcome to ENB Therapeutics. We believe that there are serious deficits in current melanoma therapies. It is our goal to offer better and more cost effective solutions for a devastating disease.
Recent Posts
- ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in Solid Tumors Refractory to Standard of Care at the Immuno-oncology Summit 2023
- ENB Therapeutics Announces Poster Presentation at the 2022 Summit for Cancer Immunotherapy
- ENB Therapeutics Announces Orphan Drug Designation Granted by FDA for ENB-003 for the Treatment of Pancreatic Cancer
- ENB Therapeutics Demonstrated Early Efficacy in Phase I Clinical Trial of ENB-003 in Combination with Pembrolizumab
- Early efficacy signals in ovarian cancer patients in ongoing Ph1 trial: Poster reporting findings presented at SITC 2020 Annual Meeting
Hi, this is a comment.
To delete a comment, just log in and view the post's comments. There you will have the option to edit or delete them.